Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.

Diez-Domingo J, Suriñach NL, Alcalde NM, Betegón L, Largeron N, Trichard M.

BMC Public Health. 2010 Aug 10;10:469. doi: 10.1186/1471-2458-10-469.

2.

Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.

Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosqueda G.

Vaccine. 2007 Aug 21;25(34):6348-58. Epub 2007 Jun 29.

PMID:
17629598
3.

Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.

Dhont P, Trichard M, Largeron N, Rafia R, Bénard S.

J Med Econ. 2008;11(3):431-48. doi: 10.3111/13696990802306162.

PMID:
19450097
4.

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.

Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M.

Vaccine. 2011 Oct 6;29(43):7463-73. doi: 10.1016/j.vaccine.2011.07.056. Epub 2011 Aug 5.

PMID:
21821085
5.

An economic analysis of rotavirus vaccination in Italy.

Giammanco MD, Coniglio MA, Pignato S, Giammanco G.

Vaccine. 2009 Jun 12;27(29):3904-11. doi: 10.1016/j.vaccine.2009.04.002. Epub 2009 Apr 24.

PMID:
19446934
6.

Cost effectiveness of a pentavalent rotavirus vaccine in Oman.

Al Awaidy ST, Gebremeskel BG, Al Obeidani I, Al Baqlani S, Haddadin W, O'Brien MA.

BMC Infect Dis. 2014 Jun 17;14:334. doi: 10.1186/1471-2334-14-334.

7.

Cost-effectiveness and potential impact of rotavirus vaccination in the United States.

Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI.

Pediatrics. 2007 Apr;119(4):684-97.

PMID:
17403839
8.

Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

Standaert B, Parez N, Tehard B, Colin X, Detournay B.

Appl Health Econ Health Policy. 2008;6(4):199-216. doi: 10.2165/00148365-200806040-00003.

PMID:
19382820
9.

Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study.

Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M; REVEAL Study Group.

J Infect Dis. 2007 May 1;195 Suppl 1:S36-S44.

PMID:
17539193
10.

Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.

Fisman DN, Chan CH, Lowcock E, Naus M, Lee V.

Vaccine. 2012 Dec 14;30(52):7601-7. doi: 10.1016/j.vaccine.2012.10.034. Epub 2012 Oct 26.

PMID:
23107595
11.

Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.

Itzler RF, Chen PY, Lac C, El Khoury AC, Cook JR.

J Med Econ. 2011;14(6):748-58. doi: 10.3111/13696998.2011.614303. Epub 2011 Sep 15.

PMID:
21919673
12.

Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain.

Imaz I, Rubio B, Cornejo AM, González-Enríquez J.

Prev Med. 2014 Apr;61:116-21. doi: 10.1016/j.ypmed.2013.12.013. Epub 2013 Dec 18.

PMID:
24360847
13.

Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.

Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM.

Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124.

PMID:
22520132
14.

Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine.

Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, Parashar UD.

Pediatrics. 2009 Mar;123(3):744-9. doi: 10.1542/peds.2008-1200.

PMID:
19254997
15.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041. Epub 2009 Oct 29.

PMID:
19879226
16.

Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.

Weycker D, Sofrygin O, Kemner JE, Pelton SI, Oster G.

Vaccine. 2009 Aug 6;27(36):4930-7. doi: 10.1016/j.vaccine.2009.06.025. Epub 2009 Jun 23.

PMID:
19555715
17.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M.

Eur J Pediatr. 2010 Nov;169(11):1379-86. doi: 10.1007/s00431-010-1242-3. Epub 2010 Jun 18.

18.

Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination.

Clarke MF, Davidson GP, Gold MS, Marshall HS.

Vaccine. 2011 Jun 24;29(29-30):4663-7. doi: 10.1016/j.vaccine.2011.04.109. Epub 2011 May 14.

PMID:
21575665
19.

[Economic evaluation of acute paediatric rotavirus gastroenteritis in France].

Huet F, Allaert FA, Trancart A, Miadi-Fargier H, Trichard M, Largeron N.

Arch Pediatr. 2008 Jul;15(7):1159-66. doi: 10.1016/j.arcped.2008.04.009. Epub 2008 Jun 3. French.

PMID:
18524550
20.

Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain.

Pérez-Rubio A, Luquero FJ, Eiros Bouza JM, Castrodeza Sanz JJ, Bachiller Luque MR, de Lejarazu RO, Sánchez Porto A.

Infez Med. 2011 Sep;19(3):166-75.

Supplemental Content

Support Center